AbbVie Inc.
$514.13B- Market cap
- $454.36B
- Debt
- +$65.00B
- Cash
- −$5.23B
Capital structure 87% equity / 13% debt · EV / Revenue 8.41x · EV proxy / EBITDA proxy 22.15x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $454.36B · View financials
Snapshot Sep 11, 2026, 4:00 PM ET
FY 2025 · View financials
Decision snapshot: ABBV stock price vs DIS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DIS's multiple
Needs DIS P/E.
Implied fair value · at ABBV's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 87% equity / 13% debt · EV / Revenue 8.41x · EV proxy / EBITDA proxy 22.15x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AbbVie Inc. · implied price per share
Bear
$87.89
Base
$110.94
Bull
$142.98
WALT DISNEY CO/ · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
ABBV vs PFE
Johnson & Johnson
ABBV vs JNJ
Merck & Co., Inc.
ABBV vs MRK
Eli Lilly and Company
ABBV vs LLY
Amgen Inc.
ABBV vs AMGN
Gilead Sciences, Inc.
ABBV vs GILD
Comcast Corporation
ABBV vs CMCSA
Live Nation Entertainment, Inc.
ABBV vs LYV
VAIL RESORTS INC
ABBV vs MTN
Six Flags Entertainment Corporation/NEW
ABBV vs FUN
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABBV's premium valuation is justified by sustained high growth and ROIC, then hold or avoid new buying until fundamentals accelerate further because the current multiples already price in a lot of success relative to DIS; if you do not believe that condition holds, the relative valuation argues for caution given the extreme P/E, P/S, and EV/EBITDA premiums.
ABBV trades at a massive premium to DIS across P/E, P/S, EV/EBITDA, and EV/Revenue, yet the implied price from the P/E comparison is far below ABBV's current price. The stock is also above the top end of its historical band, suggesting the market is already pricing in a rich narrative despite mixed fundamentals.
Supporting Metrics